metronidazole has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metronidazole (MNZ) is an antiprotozoal and antimicrobial agent widely used to treat patients infected with anaerobic bacteria and intestinal parasites; however, MNZ has also been shown to induce liver tumors in rodents." | 1.72 | Metronidazole enhances steatosis-related early-stage hepatocarcinogenesis in high fat diet-fed rats through DNA double-strand breaks and modulation of autophagy. ( Eguchi, A; Hayashi, SM; Inohana, M; Kawashima, M; Kobayashi, M; Makino, E; Maronpot, RR; Masuda, S; Mizukami, S; Murayama, H; Nagahara, R; Nakamura, M; Ohtsuka, R; Shibutani, M; Takahashi, N; Uomoto, S; Yamashita, R; Yoshida, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eguchi, A | 1 |
| Mizukami, S | 1 |
| Nakamura, M | 1 |
| Masuda, S | 1 |
| Murayama, H | 1 |
| Kawashima, M | 1 |
| Inohana, M | 1 |
| Nagahara, R | 1 |
| Kobayashi, M | 1 |
| Yamashita, R | 1 |
| Uomoto, S | 1 |
| Makino, E | 1 |
| Ohtsuka, R | 1 |
| Takahashi, N | 1 |
| Hayashi, SM | 1 |
| Maronpot, RR | 1 |
| Shibutani, M | 1 |
| Yoshida, T | 1 |
1 other study available for metronidazole and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Metronidazole enhances steatosis-related early-stage hepatocarcinogenesis in high fat diet-fed rats through DNA double-strand breaks and modulation of autophagy.
Topics: Animals; Autophagy; Diet, High-Fat; DNA; Humans; Lipid Metabolism; Liver; Male; Metronidazole; Mice; | 2022 |